{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/whooping-cough/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"c6240279-15ed-57da-bbbc-a009ed1fe10d","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 73f415bf-3e2f-40b7-8254-a7e005aeba01 --><h2>Clarithromycin</h2><!-- end field 73f415bf-3e2f-40b7-8254-a7e005aeba01 -->","summary":"","htmlStringContent":"<!-- begin item d8aab120-00ce-465d-a338-595d5cfe8205 --><!-- end item d8aab120-00ce-465d-a338-595d5cfe8205 -->","topic":{"id":"35659c4f-d80b-5e8b-8b62-22146482d6da","topicId":"aa36f776-3bec-44aa-ba6f-c147b57f7328","topicName":"Whooping cough","slug":"whooping-cough","lastRevised":"Last revised in January 2021","chapters":[{"id":"57f71ac2-7f00-5c54-b9dc-d2d7d9425e4f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"43ee7c18-a7d1-5aaf-b7b1-e9f8aec21522","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c127e190-a190-5b44-9ef6-9f30b6527b35","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"86a8dc5e-4401-57e4-a893-30e9405e7e8d","slug":"changes","fullItemName":"Changes"},{"id":"f0e375ca-3710-5454-996c-600b6987bc09","slug":"update","fullItemName":"Update"}]},{"id":"9165fc1a-9d30-5e58-9bb2-a1b68eab43c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"39a4fa70-e2db-566b-9c9e-0be39b8be0ac","slug":"goals","fullItemName":"Goals"},{"id":"7fd8bab1-ed01-583f-925f-50b956b1065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4c330a84-fe34-5261-acf3-bcd6c9b9d2ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dab08320-4d0b-59e9-b25a-28f9cc15908b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a088fcbf-b960-56c1-a102-2cb980dc3cb0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05a22688-4243-5ec9-814d-874c82306da6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"32d067f6-839d-500a-9f89-494e3487c3fd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"76a32750-044c-5bf9-b055-60be74d61d05","slug":"definition","fullItemName":"Definition"},{"id":"ba541f69-d5c7-5bfb-bcef-ec03ceaceee7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d07a89e-bdd9-5e79-81eb-87c32d271af2","slug":"prognosis","fullItemName":"Prognosis"},{"id":"054c3198-af7f-5c25-8611-2cc61ad8a848","slug":"complications","fullItemName":"Complications"}]},{"id":"41fa1350-a42e-56da-b04d-aba216545b35","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6eb9d7f5-32ca-5aaa-b5f3-1ac34aeff0d6","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"02ae0369-3f8d-5a31-b677-d0a1d5d0e6f9","slug":"making-a-clinical-diagnosis","fullItemName":"Making a clinical diagnosis"},{"id":"0a55b0ed-e1e6-5bf2-a57c-ec4bda345338","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"95029ae8-217f-53b1-b552-1b19a63a1460","slug":"notification-confirmation","fullItemName":"Notification and confirmation"}]},{"id":"e9f5a777-75d4-5e44-9222-d0679a35b79f","fullItemName":"Management","slug":"management","subChapters":[{"id":"be786901-8aa4-5cf6-977f-07c667507f85","slug":"management-of-whooping-cough","fullItemName":"Scenario: Management of whooping cough"}]},{"id":"73184dce-2f33-555a-99f5-1f7676165d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6240279-15ed-57da-bbbc-a009ed1fe10d","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"f55a7bd1-232f-5264-b591-1615754d7cd4","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"69df3991-1f78-5988-a277-eba775516ffc","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"83991d80-1c24-5213-80d8-d98f94f7165f","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"9e55dced-d32c-53b0-9767-ec433fb86549","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"6a290b31-ff8d-56f2-aa28-4f7fc47c5ff6","slug":"ibuprofen","fullItemName":"Ibuprofen"}]},{"id":"0cb3e998-9c97-56e6-86e8-373f09a16cee","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06233f93-f6af-5a86-a0d3-f66b18e22f6f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"933608bb-6634-5ada-9704-c47966180200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b65931da-6bf7-5353-a3e6-b7b3f0da241d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e63923e-f250-5bb8-b436-8c4426b094d4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8a644bf0-15a8-56ea-a310-b3625c09b8ce","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4da49df8-81c2-588b-aaf2-014b7ddf9181","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"20d6c374-e4e4-55e9-8247-f63253537476","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"73184dce-2f33-555a-99f5-1f7676165d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"10c878d2-ba33-5417-bef7-360f7b7ee646","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field d56c268f-0dba-4355-acef-1c8fc6bc1a42 --><h3>Dosing information</h3><!-- end field d56c268f-0dba-4355-acef-1c8fc6bc1a42 -->","summary":"","htmlStringContent":"<!-- begin item d24d4278-e40a-4749-b6c0-90266de71fcc --><!-- begin field e0e0b8fd-4df7-450a-aedf-7ec2b64f13b1 --><ul><li><strong>In neonates, infants, and children, </strong>prescribe clarithromycin for 7 days:<ul><li>Body weight under 8 kg: 7.5 mg/kg twice a day.</li><li>Body weight 8–11 kg: 62.5 mg twice a day.</li><li>Body weight 12–19 kg: 125 mg twice a day.</li><li>Body weight 20–29 kg: 187.5 mg twice a day.</li><li>Body weight 30–40 kg: 250 mg twice a day.</li></ul></li><li><strong>In children aged 12 years and over, and adults, </strong>prescribe 500 mg twice a day for 7 days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF for Children, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">PHE, 2016b</a>]</p><!-- end field e0e0b8fd-4df7-450a-aedf-7ec2b64f13b1 --><!-- end item d24d4278-e40a-4749-b6c0-90266de71fcc -->","subChapters":[]},{"id":"f67e5cd8-640f-57dc-8fda-9afb22bb61fc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 682c1e53-e78b-4525-b92c-84715212a118 --><h3>Contraindications and cautions</h3><!-- end field 682c1e53-e78b-4525-b92c-84715212a118 -->","summary":"","htmlStringContent":"<!-- begin item d9fc675f-ad54-426d-9ec9-d8e1372ff734 --><!-- begin field faa3e717-962c-4aff-a0d9-0ce67fea134a --><p><strong>Do not prescribe clarithromycin to people:</strong></p><ul><li>With severe hepatic impairment in combination with renal impairment.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointes.</li></ul><p><strong>Prescribe clarithromycin with caution </strong><strong>to people with:</strong></p><ul><li>Mild to moderate hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is mainly excreted by the liver.</li><li>Moderate to severe renal impairment.<ul><li>Use half the normal dose in severe renal impairment (eGFR less than 30 mL/min). Avoid Klaricid XL<sup>® </sup>(clarithromycin prolonged-release once daily tablets) in people with eGFR less than 30 mL/min, as the dose cannot be reduced.</li></ul></li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>]</p><!-- end field faa3e717-962c-4aff-a0d9-0ce67fea134a --><!-- end item d9fc675f-ad54-426d-9ec9-d8e1372ff734 -->","subChapters":[]},{"id":"fd497b15-6a9c-5f2c-be0f-70c11f8e85f6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8dac9372-db54-45cd-b864-738af3201b83 --><h3>Adverse effects</h3><!-- end field 8dac9372-db54-45cd-b864-738af3201b83 -->","summary":"","htmlStringContent":"<!-- begin item 3c0e5e5c-feff-4076-a47a-18dfa7412cf6 --><!-- begin field d3482152-1a4f-4653-9f97-f77b768cb2c8 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea </strong>are the most common adverse effects of macrolides, but they are milder and less frequent with clarithromycin than with erythromycin.</li><li><strong>Consider pseudomembranous colitis </strong>if a person develops severe diarrhoea during or after treatment with clarithromycin.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis </strong>is rarely associated with clarithromycin.</li><li><strong>Hepatotoxicity (including cholestatic jaundice) and rash </strong>have been reported following treatment with clarithromycin.</li><li><strong>Reversible hearing loss (sometimes with tinnitus) </strong>can occur after large doses of clarithromycin (1–2 g).</li><li><strong>Other adverse effects reported rarely or very rarely include </strong>pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>]</p><!-- end field d3482152-1a4f-4653-9f97-f77b768cb2c8 --><!-- end item 3c0e5e5c-feff-4076-a47a-18dfa7412cf6 -->","subChapters":[]},{"id":"90e61447-bc04-5b3a-9595-e971dd781573","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 73b563b2-56a2-4340-9f01-098e04a73f37 --><h3>Drug interactions</h3><!-- end field 73b563b2-56a2-4340-9f01-098e04a73f37 -->","summary":"","htmlStringContent":"<!-- begin item f18f7ffd-dd8e-4f46-bf7a-851a2adc0fe9 --><!-- begin field ebd27224-2ec2-47cf-9648-cb956b268c11 --><ul><li><strong>Carbamazepine — </strong>clarithromycin inhibits the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin.</li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Warfarin — </strong>occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if clarithromycin is taken with atorvastatin or simvastatin.<ul><li>For simvastatin — do not prescribe clarithromycin to a person taking simvastatin, as simvastatin is extensively metabolised by CYP3A4. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin — avoid concurrent use with clarithromycin, as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Other statins — clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Calcium channel blockers (CCB's) — </strong>due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCB's metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Oral hypoglycaemic drugs and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs (such as sulphonylureas) and/or insulin can result in significant hypoglycaemia. Careful monitoring of glucose levels is recommended.</li><li><strong>Drugs that prolong the QT interval </strong>(such as haloperidol, sotalol, terfenadine, and pimozide) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia </strong>(such as diuretics, corticosteroids, short-acting beta<sub>2</sub>-agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/whooping-cough/references/\">BNF 72, 2016</a>]</p><!-- end field ebd27224-2ec2-47cf-9648-cb956b268c11 --><!-- end item f18f7ffd-dd8e-4f46-bf7a-851a2adc0fe9 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}